ORAMED PHARMACEUTICALS INC.: retained earnings or deficit
Retained earnings or deficit for ORAMED PHARMACEUTICALS INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ORAMED PHARMACEUTICALS INC. financial histories
What this measure means
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
Exact concept: us-gaap:RetainedEarningsAccumulatedDeficit. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-08-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -123,436,000 | USD | 2026-03-26 | 10-K · 0001213900-26-034835 |
| At date | 2024-12-31 | -176,616,000 | USD | 2026-03-26 | 10-K · 0001213900-26-034835 |
| At date | 2023-12-31 | -157,556,000 | USD | 2025-03-27 | 10-K · 0001013762-25-003450 |
| At date | 2022-12-31 | -163,081,000 | USD | 2024-03-06 | 10-K · 0001213900-24-020485 |
| At date | 2021-12-31 | -126,520,000 | USD | 2023-03-06 | 10-K · 0001213900-23-017837 |
| At date | 2021-08-31 | -114,852,000 | USD | 2021-11-24 | 10-K · 0001213900-21-062009 |
| At date | 2020-08-31 | -92,614,000 | USD | 2021-11-24 | 10-K · 0001213900-21-062009 |
| At date | 2019-08-31 | -81,103,000 | USD | 2020-11-24 | 10-K · 0001213900-20-038924 |
| At date | 2018-08-31 | -69,223,000 | USD | 2019-11-27 | 10-K · 0001213900-19-024940 |
| At date | 2018-05-31 | 700,000 | USD | 2018-11-28 | 10-K · 0001213900-18-016666 |
| At date | 2017-08-31 | -56,496,000 | USD | 2018-11-28 | 10-K · 0001213900-18-016666 |
| At date | 2016-08-31 | -46,016,000 | USD | 2017-11-29 | 10-K · 0001213900-17-012754 |
| At date | 2015-08-31 | -35,052,000 | USD | 2016-11-25 | 10-K · 0001213900-16-018954 |
| At date | 2014-08-31 | -27,820,000 | USD | 2015-11-25 | 10-K · 0001213900-15-009096 |
| At date | 2013-08-31 | -22,124,000 | USD | 2014-11-14 | 10-K · 0001178913-14-003555 |
| At date | 2012-08-31 | -17,891,777 | USD | 2013-11-27 | 10-K · 0001178913-13-003442 |
| At date | 2011-08-31 | -14,547,299 | USD | 2012-12-12 | 10-K · 0001178913-12-003413 |
Related financial histories
- ORAMED PHARMACEUTICALS INC.: total assets
- ORAMED PHARMACEUTICALS INC.: stockholders equity
- ORAMED PHARMACEUTICALS INC.: cash and cash equivalents
- ORAMED PHARMACEUTICALS INC.: net income or loss
- ORAMED PHARMACEUTICALS INC.: operating cash flow
- ORAMED PHARMACEUTICALS INC.: capital expenditure payments
- ORAMED PHARMACEUTICALS INC.: revenue
- ORAMED PHARMACEUTICALS INC.: financing cash flow
- ORAMED PHARMACEUTICALS INC.: investing cash flow
- ORAMED PHARMACEUTICALS INC.: basic weighted-average shares
- ORAMED PHARMACEUTICALS INC.: diluted weighted-average shares
- ORAMED PHARMACEUTICALS INC.: basic earnings per share
- ORAMED PHARMACEUTICALS INC.: diluted earnings per share
- ORAMED PHARMACEUTICALS INC.: income tax expense or benefit
- ORAMED PHARMACEUTICALS INC.: net property, plant and equipment
- ORAMED PHARMACEUTICALS INC.: share-based compensation expense
- ORAMED PHARMACEUTICALS INC.: operating income or loss
- ORAMED PHARMACEUTICALS INC.: current assets
- ORAMED PHARMACEUTICALS INC.: current liabilities
- ORAMED PHARMACEUTICALS INC.: current accounts payable
- ORAMED PHARMACEUTICALS INC.: cost of revenue
- ORAMED PHARMACEUTICALS INC.: research and development expense
Inspect the source
- Entity
- ORAMED PHARMACEUTICALS INC. / CIK 0001176309
- Captured
- 2026-09-20T07:44:51.277Z
- SEC response SHA-256
4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))